Holen Sie sich die Stockscreener-App
4.975
0.10%
0.005
Bluebird Bio Inc Aktie (BLUE) Neueste Nachrichten
Beta thalassemia Market: Epidemiology, Therapies, Companies, - openPR.com
Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates - MSN
bluebird bio updates terms of Carlyle, SK Capital buyout By Investing.com - Investing.com Canada
Carlyle and SK Capital boost Bluebird Bio bid, offering flexible payout terms - Private Equity Insights
Bluebird: Q1 Earnings Snapshot - New Haven Register
Carlyle Group, SK Capital secure all regulatory approvals to acquire bluebird bio - MSN
Bluebird Bio (BLUE) Surges on Amended Deal with Carlyle and SK C - GuruFocus
bluebird bio, Inc. SEC 10-Q Report - TradingView
Bluebird, Private Equity Firms Look To Sweeten Buyout Deal - insights.citeline.com
Bluebird Bio Shareholders Get New All-Cash Offer From Private Equity - Benzinga
bluebird bio shares soar after amended buyout offer from Carlyle, SK Capital - Proactive Investors
Bluebird Bio Stock Skyrockets on Revamped Buyout Offer - RagingBull
SK, Carlyle bolster bluebird bio bid; Therini Bio raises $39M - Endpoints News
Bluebird Bio's Acquisition Deal Offers Shareholders New Cash Option - Finimize
Bluebird bio investor reluctance pays off as Carlyle, SK improve buyout offer by 67% - Fierce Pharma
Bluebird Bio Stock Soars On Higher Upfront Payment Under Amended Merger Deal: Retail Gets More Bullish - MSN
Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital - Reuters
Bluebird bio soars on amended deal with Carlyle, SK Capital - MSN
Carlyle, SK Capital Partners and bluebird bio Amend Merger Agree - GuruFocus
Bluebird Bio (BLUE) Amends Deal with SK Capital for Shareholder Options | BLUE Stock News - GuruFocus
Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement - BioSpace
Bluebird Bio Takeover Bid: Shareholder Decision on $5 Per Share OfferNews and Statistics - IndexBox
Bluebird bio soars on amended deal with Carlyle, SK Capital (BLUE:NASDAQ) - Seeking Alpha
Bluebird Bio Amends Merger Agreement with Carlyle - TipRanks
bluebird bio stock soars 50% on improved buyout offer By Investing.com - Investing.com South Africa
bluebird bio stock soars 50% on improved buyout offer - Investing.com
Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement | BLUE Stock News - GuruFocus
bluebird bio updates terms of Carlyle, SK Capital buyout - Investing.com
Bluebird bio warns of potential bankruptcy as buyout faces another delay - Fierce Pharma
Bluebird bio, Inc.(NasdaqGS: BLUE) dropped from S&P TMI Index - marketscreener.com
Bluebird bio, Inc.(NasdaqGS: BLUE) dropped from S&P Global BMI Index - marketscreener.com
Important Information for bluebird bio Stockholders to Tender Sh - GuruFocus
Gene Therapy Market Set for Strong Growth with Ongoing Rare - openPR.com
Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital | BLUE Stock News - GuruFocus
Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital - Yahoo Finance
Learn to Evaluate (BLUE) using the Charts - news.stocktradersdaily.com
bluebird bio, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your RightsBLUE - ACCESS Newswire
bluebird bio, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before May 28, 2024 to Discuss Your RightsBLUE - ACCESS Newswire
Shareholders that lost money on bluebird bio, Inc. (BLUE) should contact Levi & Korsinsky about pending Class ActionBLUE - ACCESS Newswire
Shareholders that lost money on bluebird bio, Inc. (BLUE) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
BLUE LAWSUIT ALERT: Levi & Korsinsky Notifies bluebird bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Levi & Korsinsky Notifies bluebird bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – BLUE - ACCESS Newswire
Investors in bluebird bio, Inc. Should Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights – BLUE - ACCESS Newswire
DEADLINE ALERT: Bernstein Liebhard LLP Reminds bluebird bio, Inc. Investors of Upcoming Deadline - ACCESS Newswire
Bluebird bio, Carlyle-SK Deal Clears Regulatory Hurdles - marketscreener.com
Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio - BioSpace
Carlyle And Sk Capital Receive All Required Regulatory Approvals To Complete The Acquisition Of Bluebird Bio - marketscreener.com
bluebird bio nears acquisition by Carlyle and SK Capital - Investing.com
Bluebird Bio (BLUE) Nears Acquisition Completion Following Regulatory Approvals | BLUE Stock News - GuruFocus
Final Regulatory Approvals Secured: bluebird bio's $9.84 Per Share Buyout Faces Critical May 12 Deadline - Stock Titan
1.51%
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):